Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Plasma membrane Ca2+-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents
Xu Wu, … , Gary E. Shull, Jeffery D. Molkentin
Xu Wu, … , Gary E. Shull, Jeffery D. Molkentin
Published March 16, 2009
Citation Information: J Clin Invest. 2009;119(4):976-985. https://doi.org/10.1172/JCI36693.
View: Text | PDF
Research Article Cardiology

Plasma membrane Ca2+-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents

  • Text
  • PDF
Abstract

How Ca2+-dependent signaling effectors are regulated in cardiomyocytes, given the extreme cytoplasmic Ca2+ concentration changes that underlie contraction, remains unknown. Cardiomyocyte plasma membrane Ca2+-ATPase (PMCA) extrudes Ca2+ but has little effect on excitation-contraction coupling, suggesting its potential role in controlling Ca2+-dependent signaling effectors such as calcineurin. We generated cardiac-specific inducible PMCA4b transgenic mice that displayed normal global Ca2+ transient and cellular contraction levels and reduced cardiac hypertrophy following transverse aortic constriction (TAC) or phenylephrine/Ang II infusion, but showed no reduction in exercise-induced hypertrophy. Transgenic mice were protected from decompensation and fibrosis following long-term TAC. The PMCA4b transgene reduced the hypertrophic augmentation associated with transient receptor potential canonical 3 channel overexpression, but not that associated with activated calcineurin. Furthermore, Pmca4 gene–targeted mice showed increased cardiac hypertrophy and heart failure events after TAC. Physical associations between PMCA4b and calcineurin were enhanced by TAC and by agonist stimulation of cultured neonatal cardiomyocytes. PMCA4b reduced calcineurin nuclear factor of activated T cell–luciferase activity after TAC and in cultured neonatal cardiomyocytes after agonist stimulation. PMCA4b overexpression inhibited cultured cardiomyocyte hypertrophy following agonist stimulation, but much less so in a Ca2+ pumping–deficient PMCA4b mutant. Thus, Pmca4b likely reduces the local Ca2+ signals involved in reactive cardiomyocyte hypertrophy via calcineurin regulation.

Authors

Xu Wu, Baojun Chang, N. Scott Blair, Michelle Sargent, Allen J. York, Jeffrey Robbins, Gary E. Shull, Jeffery D. Molkentin

×

Figure 4

Pmca4b overexpression attenuates Trpc3-enhanced cardiac hypertrophy.

Options: View larger image (or click on image) Download as PowerPoint
Pmca4b overexpression attenuates Trpc3-enhanced cardiac hypertrophy.
(A)...
(A) Heart weight normalized to body weight in Trpc3 transgenic and TTG mice containing the Trpc3, tTA, and Pmca4b transgenes (*P < 0.05 versus sham, #P < 0.05 versus Trpc3 TAC). (B) Lung weight normalized to body weight (LW/BW) in Trpc3 and TTG mice after 2 weeks of TAC or a sham procedure (*P < 0.05 versus sham, #P < 0.05 versus Trpc3 TAC). (C) Cardiac fractional shortening in Trpc3 and TTG mice after 2 weeks of TAC or a sham procedure (*P < 0.05 versus sham, #P < 0.05 versus Trpc3 TAC). (D) Western blot for Trpc3 protein expression levels in Trpc3 single transgenic and TTG hearts. GAPDH is shown as a loading control. The number of mice used is shown within the bars of the various graphs.

Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts